Trial Results

October 13, 2022

Trial Results: ECOG-ACRIN Completes the First Randomized Phase 3 Clinical Trial of Neoadjuvant Immunotherapy in Patients with Kidney Cancer

The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma